ArticlePloS one2017
Risk of second primary malignancies among patients with prostate cancer: A population-based cohort study.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Risk of secondary rectal cancer and colon cancer after radiotherapy for prostate cancer: a meta-analysis.International journal of colorectal disease · 2018Pooled it
- Effects of Radiation Therapy on the Incidence of Bladder Cancer and Rectal Cancer in Patients with Prostate Cancer: A Nationwide Nested Case-Control Study in Korean Population.The world journal of men's health · 2026Article
- Article
- Risk of second primary malignancies in prostate cancer patients: A Surveillance, Epidemiology, and End Results population-based study.Asian journal of urology · 2026Article
- Synchronous/Metachronous Prostate Cancer with Other Cancer Sites-The Experience of a Single Center in Romania.Medicina (Kaunas, Lithuania) · 2025Article
- Double Primary Cancer of the Prostate and Urothelial Cancer: A Single Institution Experience.Journal of personalized medicine · 2024Article
- Review
- Risk of secondary malignancy following radiation therapy for prostate cancer.Scientific reports · 2023Article
- Treatment burden in survivors of prostate and colorectal cancers: a qualitative interview study.BMJ open · 2023Article
- Estimating the risk of developing secondary hematologic malignancies in patients with T1/T2 prostate cancer undergoing diverse treatment modalities: A large population-based study.Cancer medicine · 2021Article
- Metachronous prostate and colon adenocarcinomas.BMJ case reports · 2021Article
- Clinical characteristics and overall survival nomogram of second primary malignancies after prostate cancer, a SEER population-based study.Scientific reports · 2021Article
- High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis.Cancer management and research · 2019Review
- Prostate cancer survivors: Risk and mortality in second primary cancers.Cancer medicine · 2018Article
- Metabolic characterization and pathway analysis of berberine protects against prostate cancer.Oncotarget · 2017Article
- Complex DNA Damage: A Route to Radiation-Induced Genomic Instability and Carcinogenesis.Cancers · 2017Review
- An introduction to male breast cancer for urologists: epidemiology, diagnosis, principles of treatment, and special situations.International braz j urol : official journal of the Brazilian Society of UrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe rising incidence and life expectancy associated with prostate cancer (PCa) has led to increasing interest in predicting the risk of second primary malignancies (SPMs) among PCa survivors, although data regarding SPMs after PCa are controversial.
methodsWe identified 30,964 patients from the National Health Insurance Research Database in Taiwan who had newly diagnosed PCa between 2000 and 2010. Each patient was randomly frequency-matched with an individual without PCa, based on age, comorbidity, and index year. Competing-risks regression models were used to estimate subhazard ratios (SHRs) of SPMs development associated with PCa. The Bonferroni adjustment was used in multiple comparisons.
resultsMen with PCa had a trend of lower risk of developing overall SPMs compared to those without PCa (adjusted SHR = 0.94, 99.72% confidence interval [CI] = 0.89-1.00, p = 0.06). The risks of lung and liver cancer were significantly lower. In contrast, these patients had a significantly higher risk of thyroid cancer. There is a trend for a higher risk of developing SPMs in the urinary bladder and rectum/anus. Further analyses indicated that PCa patients who received radiation therapy (RT) had an increased risk of overall SPMs, hematologic malignancies, esophageal cancer, liver cancer, lung cancer, and urinary bladder cancer compared with those who did not receive RT.
conclusionMen with PCa tended to have a lower risk of SPMs, but a significantly higher risk of subsequent thyroid cancer. Continued cancer surveillance is required among PCa survivors, especially in specific sites and in individuals who received RT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.